Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.

Pharvaris is dedicated to advancing treatments for organ-specific auto-immune diseases that currently lack therapeutic options. We strive to leverage both scientific and business acumen, to develop better and safer treatments.

Pharvaris’ long-term goal is to become a global leader in the research, development, and commercialization of treatments for chronic rare auto-immune conditions.

Pharvaris has been recognized as one of the fastest growing companies in Europe with several notable awards, including the EY Entrepreneur Of The Year Dutch National Finalist in 2020 and Deloitte Fast50 Technology Award in 2021.